OPDIVO 10 mg/mL concentrate for solution for infusion., Anti-Fucosyl GM1 PET Tracer, ETOPOSIDE, CARBOPLATIN clinical trials

A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer

This study is looking at a new treatment combination for a type of lung cancer called extensive-stage small cell lung cancer. It combines an approved drug (Nivolumab, also known as OPDIVO) with two standard chemotherapy drugs and a new study drug, BMS-986012, to see if it helps patients.